From the best hiking boots to the best camping storage boxes, outdoor gear is in my blood. I love to hike, bike, run, swim, paddle and scramble. I’m also an outdoors-focused strength coach who helps ...

A lightweight pack that’s well ventilated and that has loads of smart touches to make your hikes a little more comfortable ...

A Ground Self-Defense Force V-22 Osprey transport aircraft suffered damage in an accident that occurred when it took off during training on Sunday, leading the GSDF to suspend flights of all of ...

I used both a bladder system and carried a collapsible water bottle as well. I recommend the Osprey - I have been using 2L version for several years now, no leaking issues. It has a nice wide mouth ...

Lesh had previously survived bouts of prostate cancer, bladder cancer and a 1998 liver transplant necessitated by the debilitating effects of a hepatitis C infection and years of heavy drinking.

Overactive bladder (OAB) is a group of symptoms that are not usually life-threatening but can significantly decrease productivity and quality of life. The condition is characterized by the sudden need ...

So I used my stock whistle on my Osprey bag. Now I have blown this thing many times to the annoyance of my dear wife and it seemed loud but not on this day, the environment swallowed up the piercing ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead ...

The setback in bladder cancer is a small disappointment, representing less than 10% of sales compared with 90% in breast cancer, TD Securities analyst Tyler Van Buren wrote in a note to clients. Van ...